Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-1777 · 1 trial · 1 indication
The EASI evaluation was performed by the Principal Investigator and evaluated atopic dermatitis in each of 3 body regions (trunk \[excluding groin and genitalia\], upper extremities \[excluding palms of hands\], and lower extremities \[excluding soles of feet\]). The EASI scoring system uses a defined process to grade the severity of the signs of atopic dermatitis and the extent affected. EASI Scores ranged from 0-72, with higher scores indicative of more severe disease.
| Arm | Type | Description |
|---|---|---|
| ATI-1777 | EXPERIMENTAL | ATI-1777 topical solution 2.0% w/w, twice daily |
| Vehicle | PLACEBO_COMPARATOR | Vehicle topical solution, twice daily |
| Name | Type | Description |
|---|---|---|
| ATI-1777 | DRUG | ATI-1777 topical solution 2.0% w/w |
| Vehicle | DRUG | Vehicle topical solution containing no ATI-1777 |
Inclusion Criteria: 1. Able to comprehend and willing to sign the IRB approved informed consent form (ICF) prior to administration of study-related procedures. 2. Male patients or non-pregnant, non-nursing female patients 18 to 65 years old, inclusive, at the time of informed consent. 3. Pregnancy ...
Top 20 of 26 competitors
ATI-1777 is an investigational small molecule being developed by Aclaris Therapeutics, Inc. for the treatment of atopic dermatitis. It is a topical kinase inhibitor that targets JAK1 and JAK3. ATI-1777 has completed a Phase 2 clinical trial in adults with moderate or severe atopic dermatitis.
ATI-1777 is being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. The clinical program has focused on adult patients with moderate or severe forms of the disease. It remains investigational and has not been approved for commercial use.
ATI-1777 targets JAK1 and JAK3, two members of the Janus kinase family of enzymes. These kinases are part of the JAK-STAT signaling pathway, which transmits cytokine signals involved in inflammation. By inhibiting JAK1 and JAK3, ATI-1777 is designed to reduce inflammatory signaling in the skin.
ATI-1777 is being developed by Aclaris Therapeutics, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol ACRS. Aclaris is the sponsor of the clinical program evaluating the drug in atopic dermatitis.
ATI-1777 is in Phase 2 development. A Phase 2 trial in adult patients with moderate or severe atopic dermatitis has been completed. The drug is investigational and has not been approved by the FDA for any indication.
ATI-1777 has been studied in one clinical trial, NCT04598269, titled Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis. This completed Phase 2 trial enrolled 50 participants in the United States. It was randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.